Tsukuba, Japan

Yasuhiko Shinguh

This inventor holds 1 USPTO granted patent. Top assignee: Fujisawa Pharmaceutical Company, Ltd.. Active years: 1994.


% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1994

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yasuhiko Shinguh: Innovator in Therapeutic Composition

Introduction

Yasuhiko Shinguh is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of medicine, particularly in the development of therapeutic compositions. His work focuses on addressing critical health conditions, showcasing his dedication to improving patient outcomes.

Latest Patents

Yasuhiko Shinguh holds a patent for a prophylactic and therapeutic composition aimed at treating disseminated intravascular coagulation and chronic respiratory tract infectious diseases. The patent describes a method for therapy that involves administering an effective dose of WS7622A mono- or di-sulfate ester or their pharmaceutically acceptable salts to patients in need of treatment.

Career Highlights

Shinguh is associated with Fujisawa Pharmaceutical Company, Ltd., where he has been instrumental in advancing pharmaceutical research and development. His innovative approach has led to the creation of effective therapeutic solutions that address complex medical conditions.

Collaborations

Throughout his career, Yasuhiko Shinguh has collaborated with esteemed colleagues, including Masami Ezaki and Shigehiro Takase. These partnerships have fostered a collaborative environment that enhances the quality and impact of their research.

Conclusion

Yasuhiko Shinguh's contributions to the field of medicine through his innovative patents and collaborations highlight his commitment to advancing healthcare solutions. His work continues to inspire future innovations in therapeutic treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…